APR Applied Pharma Research (“APR”) and Labtec GmbH (“Labtec”) announce the successful completion of the pivotal clinical study on Zolmitriptan RapidFilm®, and its upcoming submission for registration in Europe.
![PR_APR_Labtec_ZOL_ODF_Sept2010_Final.pdf PR_APR_Labtec_ZOL_ODF_Sept2010_Final.pdf](/files/archives/p_PR_APR_Labtec_ZOL_ODF_Sept2010_Final.jpg)
APR Applied Pharma Research (“APR”) and Labtec GmbH (“Labtec”) announce the successful completion of the pivotal clinical study on Zolmitriptan RapidFilm®, and its upcoming submission for registration in Europe.
Linkedin